Janus tyrosine kinase (JAK) signaling may be involved in the pathogenesis of polymyalgia rheumatica (PMR), and tofacitinib may be an effective treatment, according to a pilot study published online June 29 in PLOS Medicine.
Jul 10, 2023
0
0
Systemic sclerosis—or scleroderma that affects the skin and internal organs—is one of the rarest autoimmune diseases, affecting roughly 100,000 people (primarily women) in the United States. However, systemic sclerosis ...
Oct 6, 2022
0
14
UT Southwestern researchers have identified a molecular pathway responsible for the spread of glioblastoma to surrounding tissue in the brain, as well as an existing drug that curbed tumor growth in animal models. The findings, ...
Aug 10, 2022
0
1109
A repurposed arthritis drug has shown positive results in a clinical trial of patients hospitalized with COVID-19, according to a paper published Wednesday in the New England Journal of Medicine.
Jun 17, 2021
0
7
A team of researchers led by biomedical scientist Declan F. McCole at the University of California, Riverside, has found that the drug tofacitinib, also called Xeljanz and approved by the FDA to treat rheumatoid arthritis ...
Sep 30, 2020
0
5
Tofacitinib, a Janus kinase inhibitor approved to treat rheumatoid arthritis and bowel diseases, may allow patients with celiac disease to eat gluten without experiencing intestinal and extraintestinal symptoms. A case report ...
Jul 28, 2020
0
4
A research team led by biomedical scientists at the University of California, Riverside, has found that a drug approved by the FDA to treat rheumatoid arthritis and ulcerative colitis can repair permeability defects in the ...
Dec 4, 2019
0
5
A new study found that very few serious infections were seen in children born to mothers with chronic inflammatory diseases who used non-TNFi biologics or tofacitinib during pregnancy compared to children not exposed to these ...
Nov 10, 2019
1
2
New warnings about an increased risk of thrombosis and of death among ulcerative colitis patients taking the 10 mg twice daily dose of the drug tofacitinib (Xeljanz, Xeljanz XR) have been issued by the U.S. Food and Drug ...
Jul 29, 2019
0
3
(HealthDay)—A safety clinical trial has revealed that tofacitinib (Xeljanz, Xeljanz XR) 10 mg twice daily is associated with an increased risk for pulmonary embolism (PE) and death among patients with rheumatoid arthritis ...
Mar 1, 2019
0
5
